Review: Tumor Vasculature and Microenvironment Normalization: A Possible Mechanism of Antiangiogenesis Therapy

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Biotherapy and Radiopharmaceuticals

• Publication date

  2008-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1089/cbr.2008.0492PMID 18986217
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Angiogenesis in Brain Tumors

  2013cited by this paper
• The critical role of the bone microenvironment in cancer metastases.

  2009cited by this paper
• Discrepancies Between Antiangiogenic and Antitumor Effects of Recombinant Human Endostatin

  2009cited by this paper
• Angiogenesis: an organizing principle for drug discovery?

  2007cited by this paper
• Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization.

  2007cited by this paper
• Thrombospondin-based antiangiogenic therapy.

  2007cited by this paper
• Models, mechanisms and clinical evidence for cancer dormancy

  2007cited by this paper
• Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo

  2007cited by this paper
• Scheduling of Radiation with Angiogenesis Inhibitors Anginex and Avastin Improves Therapeutic Outcome via Vessel Normalization

  2007cited by this paper
• Angiogenesis in brain tumours

  2007cited by this paper
• The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature.

  2007cited by this paper
• Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells.

  2007cited by this paper
• Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy

  2007cited by this paper
• Design of clinical trials of radiation combined with antiangiogenic therapy.

  2007cited by this paper
• Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.

  2007cited by this paper
• Molecular pathways of angiogenesis inhibition.

  2007cited by this paper
• Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions

  2007cited by this paper
• Effect of heterogeneous vasculature on interstitial transport within a solid tumor.

  2007influential reference
• Radiation combined with antiangiogenic and antivascular agents.

  2006cited by this paper
• Lessons from phase III clinical trials on anti-VEGF therapy for cancer

  2006cited by this paper
• Imaging vascular physiology to monitor cancer treatment.

  2006cited by this paper
• Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

  2005cited by this paper
• Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors.

  2005cited by this paper
• How does antiangiogenic therapy affect brain tumor response to radiation?

  2005cited by this paper
• Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients

  2005cited by this paper
• PDGFRβ+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival

  2005cited by this paper
• Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth.

  2005cited by this paper
• Changes in intratumor heterogeneity in blood perfusion in intradermal human melanoma xenografts during tumor growth assessed by DCE-MRI.

  2005cited by this paper
• Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

  2005cited by this paper
• Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

  2004cited by this paper
• MRI monitoring of Avastin™ antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer

  2004cited by this paper
• The anti-angiogenic basis of metronomic chemotherapy

  2004cited by this paper
• Quantitative assessment of uptake and distribution of iron oxide particles (NC100150) in human melanoma xenografts by contrast‐enhanced MRI

  2004cited by this paper
• Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11.

  2004cited by this paper
• Assessment of tumor blood perfusion by high‐resolution dynamic contrast‐enhanced MRI: A preclinical study of human melanoma xenografts

  2004cited by this paper
• Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

  2004cited by this paper
• Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors

  2004cited by this paper
• CORRIGENDUM: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

  2004cited by this paper
• Vascular endothelial growth factor - basic science and its clinical implications.

  2004cited by this paper
• Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors.

  2003cited by this paper
• Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts.

  2003cited by this paper
• Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.

  2003cited by this paper
• Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?

  2002cited by this paper
• Metastasis: Lymphangiogenesis and cancer metastasis

  2002cited by this paper
• Thrombospondin‐1 as an endogenous inhibitor of angiogenesis and tumor growth

  2002cited by this paper
• Molecular control of lymphangiogenesis

  2002cited by this paper
• Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours.

  2002cited by this paper
• Vascular Morphogenesis and Remodeling in a Human Tumor Xenograft: Blood Vessel Formation and Growth After Ovariectomy and Tumor Implantation

  2001cited by this paper
• Clinical implications of circulating angiogenic factors in cancer patients.

  2001cited by this paper
• Hyperglycemia-induced vasculopathy in the murine conceptus is mediated via reductions of VEGF-A expression and VEGF receptor activation.

  2001cited by this paper
• Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck

  2001cited by this paper
• Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF

  2001cited by this paper
• Development of matrix metalloproteinase inhibitors in cancer therapy.

  2001cited by this paper
• Antiangiogenesis signals by endostatin.

  2001cited by this paper
• Angiogenesis in cancer and other diseases

  2000cited by this paper
• Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.

  2000cited by this paper
• Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

  2000cited by this paper
• Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12.

  2000cited by this paper
• Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.

  1999cited by this paper
• Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo.

  1999cited by this paper
• Antiangiogenesis is produced by nontoxic doses of vinblastine.

  1999cited by this paper
• Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols

  1999cited by this paper
• VEGF contributes to postnatal neovascularization by mobilizing bone marrow‐derived endothelial progenitor cells

  1999cited by this paper
• HIF-1 alpha is required for solid tumor formation and embryonic vascularization.

  1998cited by this paper
• HIF‐1α is required for solid tumor formation and embryonic vascularization

  1998cited by this paper
• Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count, and computer image analysis

  1995cited by this paper
• Efficacy of antitumor chemotherapy in C3H mice enhanced by the antiangiogenesis steroid, cortisone acetate.

  1987cited by this paper
• Tumor angiogenesis: therapeutic implications.

  1971cited by this paper
• Transplacental carcinogenesis by stilbestrol.

  1971cited by this paper

• Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions

  2024cites this paper
• Application basis of combining antiangiogenic therapy with radiotherapy and immunotherapy in cancer treatment

  2022cites this paper
• Stimuli-responsive nanoassemblies for targeted delivery against tumor and its microenvironment.

  2022cites this paper
• Targeting SMYD2 inhibits angiogenesis and increases the efficiency of apatinib by suppressing EGFL7 in colorectal cancer

  2022cites this paper
• Redox-sensitive hyaluronic acid-cholesterol nanovehicles potentiate efficient Transmembrane internalization and controlled release for penetrated "full-line" inhibition of pre-metastatic initiation.

  2021cites this paper
• Role of Tumor Microenvironment in Cancer Stem Cells Resistance to Radiotherapy.

  2021cites this paper
• Biomimetic Models of the Microcirculation for Scientific Discovery and Therapeutic Testing

  2021cites this paper
• Circular dumbbell miR-34a-3p and −5p suppresses pancreatic tumor cell-induced angiogenesis and activates macrophages

  2020cites this paper
• Monitoring of tumor growth and vascularization with repetitive ultrasonography in the chicken chorioallantoic-membrane-assay

  2020cites this paper
• Cancer-associated fibroblast regulation of tumor neo-angiogenesis as a therapeutic target in cancer

  2019cites this paper
• Introduction to the Acquisition of Resistance to Targeted Therapy

  2019cites this paper
• Effects of Different Therapeutic Approaches on Diagnosis of Glioblastoma and Detection of Its Recurrence.

  2018cites this paper
• Effect of low dose fractionated radiation on reversing cisplatin resistance in ovarian carcinoma via VEGF and mTOR

  2017cites this paper
• Suppression of Colorectal Cancer Liver Metastasis by Apolipoprotein(a) Kringle V in a Nude Mouse Model through the Induction of Apoptosis in Tumor-Associated Endothelial Cells

  2014cites this paper
• MRI-Based Computational Model of Heterogeneous Tracer Transport following Local Infusion into a Mouse Hind Limb Tumor

  2014cites this paper
• Low-dose radiation induces antitumor effects and erythrocyte system hormesis.

  2013cites this paper
• Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature

  2013cites this paper
• Combination therapy of radiofrequency ablation and bevacizumab monitored with power Doppler ultrasound in a murine model of hepatocellular carcinoma

  2012cites this paper
• Targeted antivascular therapy with the apolipoprotein(a) kringle V, rhLK8, inhibits the growth and metastasis of human prostate cancer in an orthotopic nude mouse model.

  2012cites this paper
• The relationship between RGS5 expression and cancer differentiation and metastasis in non‐small cell lung cancer

  2012cites this paper
• Interfering growth of malignant melanoma with Ang2-siRNA

  2012cites this paper
• Integrin-Mediated Cell-Matrix Interaction in Physiological and Pathological Blood Vessel Formation

  2011cites this paper
• The effect of low-dose total body irradiation on tumor-inhibition and signal transduction in tumor tissues of mice bearing S180 sarcoma

  2011cites this paper
• Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.

  2011cites this paper
• Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab in advanced non-small-cell-lung cancer patients

  2010cites this paper
• Chemotherapy Trials for Colorectal Cancer in Advanced Disease: What’s the Current Hypothesis?

  2010cites this paper
• Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma

  2010cites this paper
• Development of Vascular Disrupting Agents

  2010cites this paper
• Discrepancies Between Antiangiogenic and Antitumor Effects of Recombinant Human Endostatin

  2009cites this paper
• The critical role of the bone microenvironment in cancer metastases.

  2009cites this paper
• Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination?

  2009cites this paper